Business Context and Reporting Period
Company: West Pharmaceutical Services, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: A global pharmaceutical technology company operating through two segments: Pharmaceutical Systems (primary packaging components for injectable drug delivery) and Tech Group (custom contract manufacturing for healthcare and consumer industries). The company is a large accelerated filer with manufacturing locations in North and South America, Europe, and Asia.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2006 |
|---|---|---|---|
| Net Sales | $242.7 | $764.0 | $681.4 |
| Gross Profit | $64.3 | $221.3 | $198.3 |
| Gross Margin | 26.5% | 29.0% | 29.1% |
| Operating Profit | $12.9 | $87.3 | $80.0 |
| Net Income | $12.2 | $64.7 | $52.1 |
| Diluted EPS (Continuing Ops) | $0.36 | $1.86 | $1.39 |
| Cash and Equivalents | $151.4 (Sep 30, 2007) | $47.1 (Dec 31, 2006) | |
| Long-Term Debt | $393.1 (Sep 30, 2007) | $235.8 (Dec 31, 2006) | |
| Working Capital | $274.4 (Sep 30, 2007) | $124.8 (Dec 31, 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11.2% in Q3 2007 and 12.1% for the nine-month period compared to 2006. Organic growth (excluding foreign currency) was 7.3% in Q3 and 8.0% year-to-date, driven by volume increases and price hikes in the Pharmaceutical Systems segment.
- Profitability Impact: Operating profit decreased 34.5% in Q3 2007 ($12.9M vs $19.7M) primarily due to an $8.6 million pre-tax charge for Brazilian tax contingencies. Excluding this charge, operating profit would have been higher than the prior year.
- Debt Structure: In March 2007, the company issued $161.5 million in 4% convertible junior subordinated debentures. This increased long-term debt significantly but also boosted cash reserves from $47.1M to $151.4M.
- Segment Performance: Pharmaceutical Systems operating profit declined slightly in Q3 due to expansion costs and R&D spending. Tech Group operating profit declined due to start-up costs at a new Michigan facility.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- Brazil Tax Contingency: An $8.6 million charge was recorded in Q3 2007 for social security and excise tax liabilities, increasing the total accrued liability to $17.7 million.
- Discontinued Operations: A $0.5 million provision was recorded for claims related to a 2005 divestiture.
- Tax Benefits: Discrete tax benefits of $4.0 million (Q3) and $6.5 million (YTD) were recognized due to the reversal of valuation allowances and the closure of prior tax audit years.
- Exubera Product Risk: Pfizer announced on October 18, 2007 (subsequent to period end) the discontinuation of the Exubera inhalation device. West believes its $15.0 million in current assets and production facilities are recoverable under contract, but a $13.1 million intangible asset may require impairment evaluation.
- Outlook:
- Capital spending for 2007 is projected at approximately $120 million, reduced by $10 million due to delays in China facility approvals.
- Management expects the new Michigan facility to reach full capacity in Q4 2007 and return to positive gross profit contribution in Q1 2008.
- Renegotiations with four of the largest customers are expected to conclude in Q4 2007.
- Risks: Dependence on third-party suppliers, raw material price escalation (petroleum-based), currency fluctuations, and the commercial success of customer products.
Investor Verification Checklist
- Brazil Tax Liability: Verify the status of the $17.7 million accrued tax liability and the timeline for "judicial deposits" intended to stop interest accrual.
- Exubera Impairment: Monitor the evaluation of the $13.1 million intangible asset related to the Exubera contract following Pfizer's discontinuation announcement.
- Contract Renewals: Track the outcome of negotiations with the four largest customers scheduled for completion in Q4 2007.
- China Expansion: Confirm receipt of regulatory approvals and land use rights for the planned manufacturing facilities in China.
- Michigan Facility: Validate the timeline for the new Michigan facility to achieve full capacity and positive gross profit contribution as projected for Q1 2008.